News
5d
Pharmaceutical Technology on MSNVertex wins European approval for Alyftrek, bolstering cystic fibrosis strongholdWith its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...
Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...
A small group of Australians with the rarest kinds of cystic fibrosis – fewer than 200 people – will, for the first time, ...
North Carolina man created a foundation to help other patients navigate expenses of an unexpectedly longer life ...
More Australians living with rarer types of cystic fibrosis will be able to access treatment for the first time when expanded ...
Take a straw and try to breathe through it. That's how Tayla Purves felt before she was placed on Trikafta. Ms Purves has cystic fibrosis, a genetic disease that primarily affects the lungs and ...
Ben is running 12 marathons in 12 months to raise awareness for cystic fibrosis, a condition he's battled since childhood.
Saskatchewan expands Trikafta coverage for cystic fibrosis. By Andrew Benson Global News Posted November 22, 2024 6:53 pm. Updated November 22, 2024 7:14 pm. 2 min read.
Keating and colleagues analyzed 398 patients (median age, 31 years; 59% male; 97% white) with cystic fibrosis aged at least 12 years who possessed the F508del-minimal function mutation in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results